NCT01956188

Omega 3 in LES and APS

Efficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: University of Sao Paulo · Academic / Other
• Sex: Female
• Age: 20 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

It has been demonstrated that EPA and DHA supplementation may have anti-inflammatory properties in several chronic diseases, namely, diabetes, obesity, and in rheumatoid arthritis, although not with controversy. Systemic lupus erythematosus (SLE) and Antiphospholipid Antibody Syndrome (AAS) are autoimmune diseases characterized by a chronic inflammatory state which is associated with the disease´s clinical symptoms. Thus, we hypothesized that EPA and DHA supplementation may beneficially affect the inflammatory cytokine profile and clinical features of LES and AAS patients.

Conditions

• Systemic Lupus Erythematosus
• Primary Antiphospholipid Syndrome

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	EPA and DHA supplementation	Subjects will be given 3g/d (1,2g of DHA and 1,8g of EPA) - 5 capsules per day.
DIETARY_SUPPLEMENT	Placebo	Subjects will be given 3g/d of soy oil - 5 capsules per day.

Timeline

• Start date: 2014-05-01
• Primary completion: 2017-07-01
• Completion: 2017-12-01
• First posted: 2013-10-08
• Last updated: 2017-09-27

Locations

1 site across 1 country: Brazil